摘要
目的评价伊立替康联合奈达铂治疗复发的晚期食管癌的疗效和毒副反应。方法19例晚期食管癌接受CPT-1180mg/m2静脉滴注,d1、d8、d15;奈达铂40mg/m2静脉滴注d1、d8,每4周重复,至少2周期评价疗效。结果19例可评价,客观有效率36.8%,疾病控制率57.9%,QoL稳定率68.4%,主要毒副反应为骨髓抑制、腹泻、呕吐等,经相应处理后均能控制。结论伊立替康联合奈达铂治疗复发的晚期食管癌有一定疗效,值得进一步探讨。
Objective To evaluate the efficacy and toxicity of irinotecan combined with nedaplatin in the treatment of advanced esophageal cancer. Methods 19 cases received CPT-11 80 mg/m2 ivgtt dl,d8,dlS;nedaplatin 40 mg/m2 ivgtt dl,d8 and repeated every 28 days, at least received two cycles. Results Objective response rate of 36.8% was achieved, and DCR was 57.9%,the toxic reactions could be controlled with relative therapy. Conclusion This regimen is effective and well tolerable for esophageal cancer. It is worth to be used.
出处
《医学信息》
2008年第11期2070-2071,共2页
Journal of Medical Information
关键词
晚期食管癌
伊立替康
奈达铂
化疗
advanced esophageal cancer
irinotecan
nedaplatin
chemotherapy
